Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimi...
Main Authors: | Christopher C. Phelps, Christopher M. Walker, Jonathan R. Honegger |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/7/1351 |
Similar Items
-
Hepatitis C Vaccines, Antibodies, and T Cells
by: Naglaa H. Shoukry, et al.
Published: (2018-06-01) -
Hepatitis C virus infection in a Brazilian population with sickle-cell anemia
by: M.C.M.R. Torres, et al.
Published: (2003-03-01) -
Mechanistic Insights into Translation and Replication of Hepatitis C Virus RNA : Exploring Direct-Acting Antivirals
by: Kumar, Anuj
Published: (2018) -
HEPATITIS C VIRUS INFECTION - VIRUSOLOGICAL AND PATHOPHYSIOLOGICAL ASPECT
by: Marina Dinić, et al.
Published: (2002-01-01) -
Hepatitis C and HIV Screening
by: Merry Perry
Published: (2017-07-01)